Welcome to our dedicated page for Lgi Homes SEC filings (Ticker: LGIH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LGI Homes builds entire communities from the ground up, so every SEC filing is packed with details about land banks, lot absorption, and first-time buyer demand that can move the stock. If you have ever dug through a 300-page LGI Homes annual report 10-K searching for backlog or wondered how a sudden land deal shows up in an 8-K material event, you know the challenge.
Stock Titan’s AI reads each disclosure the moment it hits EDGAR, then delivers plain-English highlights. Compare segment margins in the latest LGI Homes quarterly earnings report 10-Q filing, receive real-time alerts on LGI Homes Form 4 insider transactions, and see executive pay straight from the proxy statement executive compensation tables—without tab-hopping or legalese.
- Instant dashboards summarising land inventory trends and community count shifts
- Push notifications for LGI Homes insider trading Form 4 transactions within minutes of filing
- Side-by-side redlines so you grasp changes between quarters
Whether you are monitoring housing-cycle timing, tracking LGI Homes 8-K material events explained, or simply understanding LGI Homes SEC documents with AI, our coverage of every form—10-K, 10-Q, 8-K, S-3, and more—turns dense text into actionable context. Save hours, spot patterns, and make informed calls with LGI Homes earnings report filing analysis that is already decoded.
GMS Inc. (GMS) Form 4 details routine equity activity by SVP & General Counsel Craig D. Apolinsky on 1 Aug 2025.
Common stock: Three RSU tranches converted into 4,119 shares (code “M”); 1,836 shares were withheld for taxes (code “F”), producing a net gain of 2,283 shares. Direct ownership now stands at 15,966 shares.
Derivative securities: After vesting, 3,294 RSUs from prior awards remain outstanding. The executive also received 6,250 new RSUs that vest in equal parts on 1 Aug 2026-2028, lifting total unvested RSUs to 9,544 units.
All transactions were automatic under the company’s equity plans; no open-market buying or discretionary selling occurred. The filing contains no financial metrics or guidance and is unlikely to be materially market-moving.
Cocrystal Pharma (COCP) filed a Form 8-K dated August 5 2025 under Item 7.01 to furnish, not file, a press release and slide deck (Exhibits 99.1 & 99.2) announcing Phase 1 safety and tolerability data for its oral, direct-acting pan-viral inhibitor CDI-988. The data were presented at the 2025 Military Health System Research Symposium (Aug 4-7, Kissimmee, FL). No financial statements, earnings metrics, or transactional details are included, and the company expressly disclaims incorporation of this information into other SEC filings. The report contains no other items and therefore has no direct financial impact disclosure. Signature by CFO & Co-CEO James Martin concludes the filing.